Predictive value of hepatic venous pressure gradient in cirrhotic portal vein thrombosis development - 15/11/24
Highlights |
• | Portal vein thrombosis (PVT) is a common complication among patients with liver cirrhosis. We found that hepatic venous pressure gradient (HVPG) independently predicted PVT. A baseline HVPG of ≥ 16 mmHg accurately identified patients at higher risk for thrombosis. |
Abstract |
Background & Aims |
There are lots of risk factors reported for cirrhotic portal vein thrombosis (PVT) development, however, the relationship between hepatic venous pressure gradient (HVPG) and PVT development remains unclear.
Methods |
The clinical outcomes of cirrhotic patients who had no PVT and underwent HVPG measurement at baseline between March 2018 and March 2022 were analyzed retrospectively. Screening for non-tumoral PVT development was implemented by contrast-enhanced computed tomography and/or magnetic resonance imaging every 6-12 months.
Results |
Eighty-two cirrhotic patients were evaluated over a follow-up period. Of these, 12 patients (14.6%) experienced the development of PVT. The occurrence of non-tumoral PVT at one, two, and three years were 6.6%, 11.7%, and 22.2% respectively. HVPG (p=0.038;HR 1.07;95%CI 1.00-1.14) and alcohol liver disease (ALD) (p=0.019;HR 4.20;95%CI 1.27-13.89) were independently associated with a high PVT risk. The cutoff value of HVPG was 17.52 mmHg. The cumulative incidence of PVT differed significantly among groups stratified by HVPG thresholds of 16mmHg (P=0.011). The sensitivity and specificity of HVPG≥16mmHg in predicting PVT development were 100.0% and 35.7%.
Conclusions |
In patients with liver cirrhosis, the value of HVPG was the independent predictive factor of PVT development. Screening for PVT was recommended during follow-up in patients with HVPG≥16 mmHg.
Le texte complet de cet article est disponible en PDF.Keywords : Portal vein thrombosis, Hepatic venous pressure gradient, Liver cirrhosis
Plan
Vol 48 - N° 10
Article 102484- décembre 2024 Retour au numéro
Article précédent
- Neighborhood opportunity is associated with completion of hepatocellular carcinoma surveillance prior to the diagnosis of hepatocellular carcinoma in patients with cirrhosis
- Joanna Jiang, Erin Bouquet, Yesung Kweon, Mohamed I. Elsaid, Dayssy A. Diaz, Lanla Conteh, Lindsay A. Sobotka
- Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study)
- David Laharie, Yoram Bouhnik, Lucine Vuitton, Amélie Biron, Gaelle Pierron, Yves Brault, Maryse Assing, Amira Bouzidi, Aurélien Amiot, Stephane Nancey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?